Orchestra BioMed Has A Clearer Trial Timeline But A Demanding Valuation

Orchestra BioMed has provided an update on its clinical trial timelines, which is positive for the company's growth prospects.

While this news may be of interest to investors, it does not have a direct impact on seafarers.